PIK3CD and acute myeloid leukemia: However, combining PI3K/Akt/mTOR inhibitors with conventional chemotherapy drugs, differentiation inducers (ATRA and/or arsenic trioxide), or innovative (e.g. TRAIL) agents could be a very effective therapeutic option for AML patients, as indicated by results obtained in pre-clinical settings.